Reaction
Metastases To Spleen reporting signals
As of the last recalculation, Metastases To Spleen appears in 411 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is BLINATUMOMAB (PRR 60.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Blinatumomab | 12 | 60.0 | 60.0 |
| Ifosfamide | 18 | 44.3 | 44.4 |
| Bendamustine Hydrochloride | 9 | 38.9 | 38.9 |
| Trametinib | 16 | 34.9 | 34.9 |
| Dabrafenib | 14 | 34.8 | 34.8 |
| Gemcitabine | 25 | 34.2 | 34.2 |
| Everolimus Tablets | 11 | 34.1 | 34.1 |
| Cytarabine | 33 | 30.2 | 30.2 |
| Gemcitabine Hydrochloride | 28 | 28.6 | 28.6 |
| Doxorubicin Hydrochloride | 16 | 25.8 | 25.8 |
| Vincristine Sulfate | 14 | 25.0 | 25.0 |
| Sorafenib | 10 | 25.0 | 25.0 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 6 | 23.4 | 23.4 |
| Niraparib | 10 | 23.4 | 23.4 |
| Abiraterone | 6 | 22.6 | 22.6 |
| Oxaliplatin | 28 | 20.4 | 20.4 |
| Vemurafenib | 4 | 17.0 | 17.0 |
| Osimertinib | 9 | 14.5 | 14.5 |